Published in Int J Nanomedicine on December 03, 2015
Zonisamide-loaded triblock copolymer nanomicelles as a novel drug delivery system for the treatment of acute spinal cord injury. Int J Nanomedicine (2017) 0.75
Self-Assembled Bifunctional Peptide as Effective Drug Delivery Vector with Powerful Antitumor Activity. Adv Sci (Weinh) (2017) 0.75
EGF and curcumin co-encapsulated nanoparticle/hydrogel system as potent skin regeneration agent. Int J Nanomedicine (2016) 0.75
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev (2004) 5.31
Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev (2001) 5.06
Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev (2008) 2.71
Nanoparticle-based targeted drug delivery. Exp Mol Pathol (2009) 2.62
Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry (2003) 2.48
Perturbation of the hydrophobic core of lipid bilayers by the human antimicrobial peptide LL-37. Biochemistry (2004) 1.86
NMR structure of the cathelicidin-derived human antimicrobial peptide LL-37 in dodecylphosphocholine micelles. Biochemistry (2008) 1.65
FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One (2013) 1.65
LL-37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR (J6-1) DNA vaccine. Leuk Res (2005) 1.51
Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev (2009) 1.49
Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model. Mol Ther (2003) 1.49
Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel. Pharm Res (2007) 1.09
Drug delivery: One nanoparticle, one kill. Nat Mater (2011) 1.06
Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials (2013) 1.04
Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res (2012) 1.03
Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm (2011) 1.03
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer (2008) 1.02
Connective tissue growth factor acts as a therapeutic agent and predictor for peritoneal carcinomatosis of colorectal cancer. Clin Cancer Res (2011) 0.97
Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy. Int J Nanomedicine (2012) 0.92
Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther (2009) 0.91
Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer. Cancer Lett (2004) 0.90
Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials (2011) 0.90
Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials (2014) 0.89
Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn(II)-phthalocyanine inspired by combination therapy for cancer. J Control Release (2013) 0.89
Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med (2006) 0.88
Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. Gynecol Oncol (2009) 0.87
Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer. Biomaterials (2012) 0.86
Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. J Pharm Pharmacol (2005) 0.86
Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes. Int J Nanomedicine (2011) 0.83
Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid. Int J Nanomedicine (2014) 0.81
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival. Eur J Surg Oncol (2006) 0.80
Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel. Eur J Pharm Biopharm (2014) 0.80
RGDS-functionalized polyethylene glycol hydrogel-coated magnetic iron oxide nanoparticles enhance specific intracellular uptake by HeLa cells. Int J Nanomedicine (2012) 0.79
LL37 peptide@silver nanoparticles: combining the best of the two worlds for skin infection control. Nanoscale (2014) 0.79
Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel. Int J Nanomedicine (2014) 0.79
Injectable thermosensitive hydrogel composite with surface-functionalized calcium phosphate as raw materials. Int J Nanomedicine (2014) 0.77
Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma. Int J Pharm (2014) 0.77